key: cord-1028451-i8fr91xl
authors: Luitel, Pankaj; Vais, Dana; Gidron, Adi
title: Successful Treatment of Persistent COVID 19 Infection in a Patient with Hypogammaglobulinemia with REGN-COV2: A Brief-Report
date: 2021-06-24
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab335
sha: 368a384564b79fb791f6c793faa10b22f0c0adb7
doc_id: 1028451
cord_uid: i8fr91xl

A 55-year-old-male patient with hypogammaglobulinemia due to previous rituximab treatment developed persistent COVID-19 pneumonia. Treatment with REGN-COV2 resulted in the clearance of the infection. Targeted anti-viral antibodies may be an important weapon in the management of immune-compromised patients infected by SARS-COV2 who fail to mount an immune response.

SARS-COV2 which causes COVID 19 infection is a global pandemic with significant morbidity and mortality. Although age, gender, comorbidities, and ethnicity are risk factors for adverse outcomes, 1 various pre-existing conditions, including hematological cancers, have also been reported to correlate with poor outcomes. 2 Anti-CD20 monoclonal antibodies such as rituximab represent the cornerstone of treatment of most patients with B-cell malignancies and, to a lesser extent, patients with autoimmune disease. 3, 4 Anti-CD20 treatment is associated with a risk of prolonged humoral immune deficiency which can last years and can hamper the ability to mount an antibody response to infection. 5 Non-sustained hypogammaglobulinemia post rituximab can persist for 42 months, while around 4% of patients had never recovered CD20 cells function. 6 A treatment standard for patients who fail to mount an antibody response to COVID 19 is yet to be defined. Convalescent plasma has been reported to be used in such patients with limited benefits. 7 We report a case of a 55year-old-man with severe hypogammaglobulinemia, following treatment for mantle cell lymphoma with rituximab-containing regimen, who developed persistent COVID 19 infection and was treated successfully with REGN-COV2 antibody after failing to clear the infection.

Our patient is a 55-year-old man with a history of mantle cell lymphoma in remission after treatment with hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose cytarabine and high dose methotrexate (Hyper-CVAD) and rituximab maintenance concluded in 2015. He subsequently developed hypogammaglobulinemia managed with monthly intravenous immunoglobulin (IVIG -Gamunex-C 65g). He developed fever, nausea, diarrhea, and generalized weakness in 1st week of December 2020. On December 12 2020, he tested positive for COVID 19 by high sensitivity PCR (nasal swab) and was subsequently admitted to hospital for COVID 19 pneumonia where he completed a course of Remdesivir and dexamethasone. His hospital stay was uneventful, and he was discharged after 5 days.

However, the patient continued to have fever, diarrhea, and weakness and lost 30 lbs over the next 4 weeks. He developed progressive dyspnea with exertion and his blood oxygen saturation decreased to 91% on room air. Empiric therapy with azithromycin and then amoxicillin-clavulanate did not improve his symptom. COVID 19 antibody test (Abbott antinucleocapsid IgG) done on January 19, 2021 was negative. Serum immunoglobulin levels IgA, IgG, and IgM levels at that time were <10 mg/dL, 479 mg/dL, and <20 mg/dL respectively. COVID 19 high sensitivity RT-PCR tests from nasopharyngeal swabs done on two different platforms on January 22 and 29, 2021 were negative. A Contrast-enhanced computed tomography (CECT) of the chest, abdomen, and pelvis done on February 3, 2021 showed bilateral diffuse ground-glass appearance consistent with COVID 19 pneumonia and no evidence of recurrence of lymphoma. Clostridium Difficile was ruled out given persistent diarrhea. To rule out other pathogens a bronchoscopy was done on February 5, 2021. Legionella, P. Jiroveci, fungal pathogens, AFB, influenza, parainfluenza, RSV, B Pertusis, C Pneumoniae and M Pneumoniae were ruled out. Other coronaviruses were excluded as well. The bronchoalveolar lavage (BAL) was positive for COVID 19 by high-sensitivity PCR with cycle numbers of 29.9 of 40 cut-off, performed on Cepheid GeneXpert, thus confirming the diagnosis of Covid 19 pneumonia. At that time his oxygen saturation was 90% at rest and decreased to 85% with ambulating 50 feet. M a n u s c r i p t Given the deteriorating clinical picture, an emergency authorization was obtained from the FDA for the use of REGN-COV2, and the patient was given the infusion of Casirivimab 1200mg and Imdevimab 1200mg on February 9, 2021 and was under observation for one hour without any complications or adverse effects during and following the therapy. His fevers have resolved within 12 hours of treatment. Within 36 hours he no longer had diarrhea. On February 11, 2021 his oxygen saturation was 99% at rest and dropped to 92% while ambulating 200 feet but returned to 99% within 2 minutes of rest. On February 18, 2021 he reported marked improvement in his stamina, appetite, and ability to ambulate. He was able to walk 200 feet and climb 2 flights of stairs without desaturation below 95%. On March 1, 2021 repeat bronchoscopy was negative for SARS-Cov2 by high sensitivity PCR. Patientreported complete recovery to pre-infection baseline. (Figure 1 )

As the SARS-COV2 pandemic swept across the globe there was an effort to find effective treatments for COVID 19. Although thousands of papers were published, the experience with managing severely immune-compromised patients is still scant. We report a case of successful treatment of persistent COVID 19 infection in a patient with acquired humoral immune deficiency due to treatment with anti-CD20 antibody rituximab for a diagnosis of mantle cell lymphoma, who failed to mount an antibody response to COVID 19 infection.

Anti-CD20 monoclonal antibodies like rituximab not only deplete malignant B-lymphocytes but also their normal counterparts, and therefore impair humoral immunity. 5 Patients with prior rituximab exposure are known to be poor responders to various types of vaccinations including influenza viruses, Haemophilus influenzae, and Streptococcus pneumoniae. 8, 9 In general, these patients have a higher risk of infections, both bacterial and viral, as was demonstrated in the past. 10 While some with Covid-19 would have a mild prolonged course and eventually develop antibodies, 11 others may develop a more ominous course. While the dynamics of T and B cells responses in successfully controlling this viral infection are not fully understood, there may be lack of coordination within the adaptive immune system with rituximab affecting the naïve B cells in the blood (which seem to be the source of neutralizing antibodies in COVID 19) resulting in an ineffective response. 12 The impact of COVID 19 on immune-deficient individuals and the optimal treatment modality is still unclear. There have been reports of patients post B cell depletion therapy or with hypogammaglobulinemia who cleared SARS-CoV2 infection on their own; however, other patients undergoing recent rituximab therapy had severe and prolonged COVID-19 infections with persistent detectable virus. 5 Treatment modalities such as remdesivir, dexamethasone, and convalescent plasma 13, 14, 15 have shown benefit in the general population. Convalescent plasma therapy has also been used in the general population of COVID 19 patients with a benefit when used with high antibody titer early (within 3 days of symptoms), 7 but did not show a mortality benefit when given late or as low titer. 16, 17 Since, in immunocompetent patients, higher antigen load would drive up the antibody titers to control infection, the monoclonal antibodies might provide a much needed booster in immunocompromised patients. M a n u s c r i p t REGN-COV2, manufactured by Regeneron Pharmaceuticals, is a combination of two SARS-CoV2 monoclonal antibodies Casirivimab and Imdevimab. These antibodies target the receptor-binding domain of the SARS-CoV2-2 spike protein, thereby preventing viral entry into human cells through the ACE2 receptor. REGN-COV2 is a synthetic drug, unlike convalescent plasma which is obtained from a human donor, thus eliminates transfusionrelated complications. REGN-COV2 is in phase III clinical trial and has been authorized by FDA for emergency use for patients with mild to moderate COVID who has a high risk of propagating to severe disease and hospitalization. 18 REGN-COV2 is not authorized for use in patients who are hospitalized, or in those who require oxygen therapy. REGN-COV2 is not approved yet for routine clinical use. Efficacy and safety are not yet fully established. 18 The pivotal study by Weinrich et.al, which lead to the approval of REGN-COV2, showed that REGN-COV2 enhanced clearance of virus, particularly in patients in whom an endogenous immune response had not yet been initiated or who had a high viral load at baseline. 19 REGN-COV2 has shown in a clinical trial to reduce COVID 19 related hospitalization of emergency room visits inpatient at high risk for disease progression within 28 days after treatment when compared to placebo. 18 Our patient showed persistent symptoms of fever, diarrhea, weight loss, and generalized weakness. His symptoms persisted for over two months and worsened even after initial hospitalization and treatment with remdesivir and dexamethasone. His lung function has deteriorated to the point of requiring oxygen therapy and he lost 15% of his bodyweight leading to severe generalized weakness and inability to function. Treatment with REGN-COV2 led to an immediate resolution of most symptoms, rapid improvement in respiratory function and functional capacity, and ultimately clearance of the infection. This case demonstrates the potential of REGN-COV2 to significantly alter the course of illness in immune-compromised patients. We believe REGN-COV2 is a promising treatment option for immune-compromised patients who are unable to mount a humoral immune response. It should be deployed early in the course of the illness or as soon as it is established that a patient is unable to develop antibodies against SARS-COV2. It is not yet known if this product would provide any long-term protection from re-infection. In this regard, it may be useful to evaluate the potential for REGN-COV2 to affect long-term passive immunity to SARS-CoV-2 in patients with humoral immunity defects.

Potential Conflicts of Interest: There are no conflicts of interest Patient Consent Statement: The patient provided written consent. All information was anonymized as much as possible. Amita Health IRB approved the treatment plan. Local standards do not require IRB approval of case reports.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

Persistent COVID-19 Pneumonia and Failure to Develop

Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Rituximab-associated hypogammaglobulinemia: incidence, predictors, and outcomes in patients with multi-system autoimmune disease

Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience

Rituximab-treated patients have a poor response to influenza vaccination

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial

Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment

Adaptive immunity to SARS-CoV-2 and COVID-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Remdesivir for the treatment of COVID-19-final report

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19

Convalescent plasma in the management of moderate covid-19 in adults in India: open-label phase II multicentre randomized controlled trial (PLACID Trial)

SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients with COVID-19

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t